Methadone vs Vivitrol
Methadone and Vivitrol are both used to treat opioid use disorder, but they sit at opposite ends of the medication spectrum. Methadone is a long-acting full opioid agonist that requires daily attendance at a federally certified clinic. Vivitrol is a monthly opioid blocker that any prescriber can order. The structural differences shape who fits each option as much as the pharmacology does.
| Attribute | Methadone | Vivitrol |
|---|---|---|
| Drug class | Full opioid agonist | Full opioid antagonist |
| FDA approval | Opioid use disorder, pain | Opioid use disorder + alcohol use disorder |
| Where dispensed | SAMHSA-certified Opioid Treatment Programs only | Any licensed clinic |
| Frequency | Daily, in person at the clinic for the first 90+ days | Once monthly |
| Take-home flexibility | Earned over months of stability | Not relevant - in-office only |
| Schedule | Schedule II controlled substance | Not controlled |
| Cravings reduction | Very strong | Moderate |
| Pre-treatment requirement | None - can start in active use | 7 to 10 days opioid-free |
| Withdrawal mitigation | Yes - directly | No |
| Cost with insurance | ~$15 to $30 per week clinic visit | Covered as J2315 |
| Cost without insurance | ~$80 to $200 per week | ~$1,500 per shot |
| Stigma factor | High - daily clinic visit visible | Low - monthly office visit |
| Discontinuation | Slow taper, weeks to months | Receptors restore in 7 to 14 days |
The clinic structure difference
Methadone is dispensed only through SAMHSA-certified Opioid Treatment Programs. There are roughly 1,800 of them in the United States. Patients show up daily, swallow methadone in front of a nurse, and leave. After several months of stable urine drug screens and counseling attendance, patients earn take-home doses. Take-home privileges max out at a 28-day supply for the most stable patients, and even that requires program approval.
Vivitrol has none of that structure. A primary care doctor can prescribe it. A psychiatrist can prescribe it. An addiction medicine specialist can prescribe it. The injection happens at the prescriber's office or any clinic that handles intramuscular medications. There is no daily attendance requirement, no urine drug screen schedule mandated by federal regulation, no take-home privilege ladder.
Who methadone fits
- Patients with long-term high-dose opioid use, especially fentanyl or methadone diversion
- Patients who have failed multiple attempts on buprenorphine or naltrexone
- Patients who need the structure of daily contact with a treatment program
- Pregnant patients with opioid use disorder (methadone is the strongest evidence base in pregnancy)
- Patients who want maximum receptor occupancy and craving suppression
Who Vivitrol fits
- Patients leaving incarceration or residential treatment, already opioid-free
- Patients in professional or licensed positions where opioid medications create career risk
- Patients with co-occurring alcohol use disorder
- Patients who want a medication that is not itself an opioid
- Patients without daily transportation to a clinic
Outcome data
Methadone has the longest evidence base of any medication for opioid use disorder, going back to the 1960s. Studies consistently show methadone produces the highest treatment retention rates of any MOUD. The Cochrane review of methadone vs placebo found methadone-treated patients were 4.4 times more likely to remain in treatment.
Vivitrol's evidence base is newer and smaller. The X:BOT trial showed it works about as well as buprenorphine once started, but with much higher induction failure (28% could not start). There is no head-to-head trial of methadone vs Vivitrol with a population both medications can serve, because the populations barely overlap.
The honest take
Methadone is for patients in deep opioid dependence who need maximum medication support. Vivitrol is for patients who have already cleared the receptors and want to keep them clear. They are not competing for the same patients. A patient who is the right candidate for methadone is not a candidate for Vivitrol, and vice versa. The clinical decision is rarely between these two options.